



23 October 2017

ASX ANNOUNCEMENT

Publication of Major Study in Leading Medical Journal

Mounting number of peer reviewed publications on positive impact of L-Dex®

Brisbane, Australia, and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage tissue composition and fluid status, is pleased to announce publication of the largest study to date in a peer-reviewed medical journal on the effectiveness of L-Dex for the screening, intervention and prevention of disease progression to irreversible stages.

As announced to market on 18 May 2017, the study was conducted by Pat Whitworth, MD, of the Nashville Breast Centre and comprised a retrospective analysis that examined 596 prospectively surveilled breast cancer patients at-risk for the development of lymphoedema from April 2010 to Nov 2016. At last follow-up, only 18 patients (3%) had unresolved clinically significant BCRL requiring Complete Decongestive Physiotherapy (CDP), a surrogate for the development of clinically significant, chronic BCRL. This major study has now just been published in The Breast Journal, a leading medical industry journal.

"This newly published manuscript adds to the mounting peer-reviewed evidence supporting the positive clinical impact of prospective surveillance using L-Dex in limiting this extremely debilitating and lifelong morbidity," commented Richard Carreon, Managing Director and CEO of ImpediMed.

Dr. Whitworth, the lead author of the study and a Breast Surgical Oncologist whose practice has been focused solely on the surgical management of breast disease for over 20 years commented that "After asking if she is going to live and will she need chemotherapy, the next concern most breast cancer patients ask about is lymphedema. Our patients' relief is palpable when we explain that we can now detect fluid accumulation and intervene - with 4 weeks of simple compression sleeve - prior to any swelling, preventing clinical lymphedema in all but a few cases. Not only does this approach prevent clinical lymphedema in most patients, it makes answering that question a pleasure. That is a huge advance from prescribing tape measures and restrictions that don't really help."

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO

Morten Vigeland, ImpediMed CFO

T: +1 (760) 585-2100

Media and Investor Contact:**In Australia:**

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[™], sold in select markets globally.

For more information, visit www.impedimed.com.